13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001920938
Total reported value
$2.7B
$2.7B
81 檔
26.9%
According to the latest 13F quarterly dataset, Braidwell LP managed an equity portfolio of $2.7B at the end of Q3 2024, spanning 81 distinct U.S. exchange-listed positions.
Braidwell LP executed strategic sector rebalancing during Q3 2024, establishing 16 new positions while fully exiting 10 holdings and trimming 24 positions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | GH 0 11-15-27Bond | Guardant Health Inc | Bond | 6.12% | — | — | |
| 2 | BBIO 2.5 03-15-27Bond | Bridgebio Pharma Inc | Bond | 4.13% | — | — | |
| 3 | NVCR 0 11-01-25Bond | Novocure LTD | Bond | 3.78% | — | — | |
| 4 | CGON | Cg Oncology Inc | Stock-Other | 3.39% | -2.22% | EXIT | |
| 5 | GMED 0.375 03-15-25Bond | Nuvasive Inc | Bond | 3.17% | — | — | |
| 6 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 3.02% | -0.07% | +5.73% | |
| 7 | NBIX | Neurocrine Biosciences Inc | Stock-Healthcare | 3.00% | -0.77% | +20.90% | |
| 8 | NEO 0.25 01-15-28Bond | Neogenomics Inc | Bond | 2.75% | -2.44% | — | |
| 9 | APGE | Apogee Therapeutics Inc | Stock-Other | 2.74% | -1.34% | EXIT | |
| 10 | APLSUSD | Apellis Pharmaceuticals Inc | Stock-Other | 2.55% | — | +410.82% | |
| 11 | IRWD 1.5 06-15-26Bond | Ironwood Pharmaceuticals | Bond | 2.34% | — | +3.34% | |
| 12 | DXCM 0.375 05-15-28Bond | Dexcom Inc | Bond | 2.33% | — | +12.09% | |
| 13 | ALGN | Align Technology Inc | Stock-Healthcare | 2.25% | — | +13.25% | |
| 14 | GH | Guardant Health Inc | Stock-Healthcare | 2.17% | -0.72% | +19.02% | |
| 15 | PODD 0.375 09-01-26Bond | Insulet Corporation | Bond | 2.17% | — | -6.18% | |
| 16 | LEGN | Legend Biotech Corp-adr | Stock-Other | 2.13% | — | -7.68% | |
| 17 | VKTX | Viking Therapeutics Inc | Stock-Healthcare | 2.08% | — | +4.52% | |
| 18 | KNSA | Kiniksa Pharmaceuticals International, plc | Stock-Other | 2.05% | -0.01% | +40.63% | |
| 19 | PEN | Penumbra Inc | Stock-Healthcare | 1.99% | -1.15% | EXIT | |
| 20 | DXCM 0.25 11-15-25Bond | Dexcom Inc | Bond | 1.99% | — | — | |
| 21 | MRVI | Maravai Lifesciences Hldgs-a | Stock-Other | 1.97% | +1.04% | -7.43% | |
| 22 | DAWNGBX | Day One Biopharmaceuticals I | Stock-Other | 1.92% | — | +60.54% | |
| 23 | SYRE | Spyre Therapeutics Inc | Stock-Other | 1.83% | +1.32% | -12.91% | |
| 24 | RGEN | Repligen CORP | Stock-Healthcare | 1.67% | +0.70% | +22.65% | |
| 25 | IRTC | Irhythm Holdings Inc | Stock-Healthcare | 1.65% | +0.48% | +48.67% | |
| 26 | TVTX 2.5 09-15-25Bond | Travere Therapeutics Inc | Bond | 1.52% | — | — | |
| 27 | ATEC 0.75 08-01-26Bond | Alphatec Holdings Inc | Bond | 1.49% | — | — | |
| 28 | ARGX | Argenx Se - Adr | Stock-Healthcare | 1.49% | -1.46% | -42.06% | |
| 29 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 1.48% | +0.53% | — | |
| 30 | INSP | Inspire Medical Systems Inc | Stock-Healthcare | 1.43% | -0.05% | -37.04% | |
| 31 | SRPT | Sarepta Therapeutics Inc | Stock-Healthcare | 1.31% | — | +352.26% | |
| 32 | BBIO 2.25 02-01-29Bond | Bridgebio Pharma Inc | Bond | 1.28% | — | -18.29% | |
| 33 | ISRG | Intuitive Surgical Inc | Stock-Healthcare | 1.27% | -0.16% | -9.15% | |
| 34 | ✓ | Avadel Pharmaceuticals PLC ADR | Stock-Other | 1.26% | — | +16.91% | |
| 35 | BCAX | Bicara Therapeutics Inc | Stock-Other | 1.20% | — | — | |
| 36 | KROS | Keros Therapeutics Inc | Stock-Other | 1.16% | — | -28.00% | |
| 37 | GKOS | Glaukos CORP | Stock-Healthcare | 1.15% | +0.32% | -37.25% | |
| 38 | MDGL | Madrigal Pharmaceuticals Inc | Stock-Healthcare | 1.11% | — | — | |
| 39 | PCVX | Vaxcyte Inc | Stock-Other | 0.96% | — | -63.19% | |
| 40 | REPL | Replimune Group Inc | Stock-Other | 0.95% | — | +203.03% | |
| 41 | ARVN | Arvinas Inc | Stock-Other | 0.90% | — | +148.34% | |
| 42 | KRYS | Krystal Biotech Inc | Stock-Healthcare | 0.87% | +0.20% | +57.39% | |
| 43 | KIDS | Orthopediatrics CORP | Stock-Other | 0.85% | +0.20% | — | |
| 44 | DXCM | Dexcom Inc | Stock-Healthcare | 0.84% | — | — | |
| 45 | BNTX | Biontech Se-adr | Stock-Other | 0.83% | — | — | |
| 46 | FNAUSD | Paragon 28 Inc | Stock-Other | 0.78% | — | -0.36% | |
| 47 | RLAY | Relay Therapeutics Inc | Stock-Other | 0.70% | — | +16.38% | |
| 48 | ATEC | Alphatec Holdings Inc | Stock-Other | 0.64% | +1.30% | +84.11% | |
| 49 | HROW | Harrow Inc | Stock-Other | 0.56% | -0.18% | EXIT | |
| 50 | CGEM | Cullinan Therapeutics Inc | Stock-Other | 0.56% | — | +567.62% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | APLSUSD | Apellis Pharmaceuticals Inc | +1.8% | +410.82% | Add |
| 2 | EWTX | Edgewise Therapeutics Inc | +1.5% | NEW | New buy |
| 3 | BCAX | Bicara Therapeutics Inc | +1.2% | NEW | New buy |
| 4 | MDGL | Madrigal Pharmaceuticals Inc | +1.1% | NEW | New buy |
| 5 | SRPT | Sarepta Therapeutics Inc | +0.9% | +352.26% | Add |
| 6 | KNSA | Kiniksa Pharmaceuticals International, plc | +0.8% | +40.63% | Add |
| 7 | DXCM | Dexcom Inc | +0.8% | NEW | New buy |
| 8 | BNTX | Biontech Se-adr | +0.8% | NEW | New buy |
| 9 | PEN | Penumbra Inc | +0.8% | +70.01% | Add |
| 10 | REPL | Replimune Group Inc | +0.7% | +203.03% | Add |
| 11 | DAWNGBX | Day One Biopharmaceuticals I | +0.6% | +60.54% | Add |
| 12 | AMPH 2 03-15-29Bond | Amphastar Pharmaceutical | +0.6% | NEW | New buy |
| 13 | ✓ | Immatics NV | +0.5% | NEW | New buy |
| 14 | ARVN | Arvinas Inc | +0.5% | +148.34% | Add |
| 15 | CGEM | Cullinan Therapeutics Inc | +0.5% | +567.62% | Add |
| 16 | BSX | Boston Scientific CORP | +0.5% | NEW | New buy |
| 17 | RGEN | Repligen CORP | +0.4% | +22.65% | Add |
| 18 | HROW | Harrow Inc | +0.4% | +47.93% | Add |
| 19 | ORKA | Oruka Therapeutics Inc | +0.4% | NEW | New buy |
| 20 | ✓ | Zura Bio LTD | +0.3% | NEW | New buy |
| 21 | PODD | Insulet CORP | +0.3% | NEW | New buy |
| 22 | XNCR | Xencor Inc | +0.3% | NEW | New buy |
| 23 | JSPR | Jasper Therapeutics Inc | +0.3% | NEW | New buy |
| 24 | KRYS | Krystal Biotech Inc | +0.3% | +57.39% | Add |
| 25 | VKTX | Viking Therapeutics Inc | +0.2% | +4.52% | Add |
| 26 | OCUL | Ocular Therapeutix Inc | +0.2% | +36.26% | Add |
| 27 | ALGN | Align Technology Inc | +0.2% | +13.25% | Add |
| 28 | FDMT | 4d Molecular Therapeutics In | +0.1% | +231.69% | Add |
| 29 | CGON | Cg Oncology Inc | +0.1% | -4.19% | Trim |
| 30 | FULC | Fulcrum Therapeutics Inc | +0.1% | NEW | New buy |
| 31 | CELC | Celcuity Inc | +0.1% | +71.16% | Add |
| 32 | ✓ | Verve Therapeutics Inc | +0.1% | NEW | New buy |
| 33 | RLAY | Relay Therapeutics Inc | +0.1% | +16.38% | Add |
| 34 | DNTH | Dianthus Therapeutics Inc | +0.1% | +34.57% | Add |
| 35 | ✓ | Hillevax Inc | +0.1% | NEW | New buy |
| 36 | LUNG | Pulmonx CORP | 0% | — | Unchanged |
| 37 | TVTX 2.5 09-15-25Bond | Travere Therapeutics Inc | 0% | — | Unchanged |
| 38 | CSTL | Castle Biosciences Inc | 0% | -20.21% | Trim |
| 39 | SYRE | Spyre Therapeutics Inc | 0% | -12.91% | Trim |
| 40 | ✓ | Avadel Pharmaceuticals PLC ADR | 0% | +16.91% | Add |
| 41 | CUTR 4 06-01-29Bond | Cutera Inc | 0% | — | Unchanged |
| 42 | ✓ | Dbv Technologies S A | 0% | -33.24% | Trim |
| 43 | HAE 0 03-01-26Bond | Haemonetics CORP | 0% | — | Unchanged |
| 44 | ETNBGBP | 89bio Inc | 0% | EXIT | Sold out |
| 45 | BBIO | Bridgebio Pharma Inc | -0.1% | -13.65% | Trim |
| 46 | CUTR 2.25 06-01-28Bond | Cutera Inc | -0.1% | — | Unchanged |
| 47 | ALEC | Alector Inc | -0.1% | -9.34% | Trim |
| 48 | MRVI | Maravai Lifesciences Hldgs-a | -0.1% | -7.43% | Trim |
| 49 | OMGBP | Outset Medical Inc | -0.1% | EXIT | Sold out |
| 50 | ATEC | Alphatec Holdings Inc | -0.1% | +84.11% | Add |
According to official SEC Form 13F filings, Braidwell LP reported a total U.S. public equity portfolio value of $2.7B across 81 disclosed positions in Q3 2024.
During Q3 2024, Braidwell LP's top holdings by market value included GH 0 11-15-27 (6.1%)、BBIO 2.5 03-15-27 (4.1%)、NVCR 0 11-01-25 (3.8%). The largest single position, GH 0 11-15-27, represented 6.1% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including GH 0 11-15-27, BBIO 2.5 03-15-27, NVCR 0 11-01-25) accounted for 26.9% of total reported equity market value during Q3 2024.
Top New Position Initiated
EWTX
市值: $52.3M
Top Position Liquidated / Trimmed
SRPT 1.25 09-15-27
前期市值: $55.5M
In Q3 2024, Braidwell LP made 76 total portfolio adjustments, initiating 16 new buys, adding to 26 positions, trimming 24 holdings, and fully liquidating 10 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.